The CHI Insight Pharma Reports Advisory Board
As the leading publisher of business intelligence focused on bio/pharmaceutical R&D, Insight Pharma Reports maintains its edge through continuous interaction with a broad network of experts including resident analysts at Cambridge Healthtech Institute and external experts throughout the life science world.
However, in order to understand and properly evaluate the challenges — business, regulatory, technological, competitive — faced by managers at life science companies, we felt the need to assemble an advisory board representing broad expertise throughout the pharmaceutical value chain. The CHI Insight Pharma Reports Advisory Board is our window into emerging developments in industry — our canaries in the coal mine.
We are pleased to present the following charter members:
|
|
|
Abe Abuchowski, PhD
- CEO, Prolong Pharmaceuticals
- Co-founder, Enzon, Inc.
- Co-inventor of PEGylation technology
|
Orest Hurko, MD
- Assistant Vice President, Translational Research, Wyeth
- Interim Director, Translational Medicine Research Centre, Dundee, Scotland/Wyeth
|
David Lester, PhD
- New York Site Head, Human Health Technologies, Global Clinical Technologies, Pfizer
- Former Senior Science Director, CDER, FDA
|
|
|
|
|
|
|
James Resch, PhD
- Director, Strategic Intelligence, Global Discovery Strategy, Portfolio, & Project Evaluation, AstraZeneca
|
Michael Stocum, MS
- Managing Director, Personalized Medicine Partners, LLC
- Vice President, Business Development and Corporate Strategy, Tricon Pharmaceuticals
|
Michael H. Silverman, MD, FACP
- Founder and President, BioStrategics Consulting Ltd
|